Deliberate AI

Deliberate AI is a digital health technology company founded in 2020 that focuses on delivering precision measurement of mental health through artificial intelligence. The company's flagship product is the AI-generated Clinical Outcome Assessment (AI-COA), an assessment tool for anxiety and depression. AI-COA uses advanced multimodal behavioral signal processing and machine learning to quantitatively capture mental health symptoms. This technology analyzes audiovisual signals captured through smartphones or computers, combining data from sight and hearing to provide a consistent and bias-free assessment method. The AI-COA tool is designed to augment human clinical assessments during clinical trials, improving precision and reliability in measuring mental health symptoms. In January 2024, Deliberate AI's AI-COA was selected by the US Food and Drug Administration (FDA) for inclusion in the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program, marking it as the first AI/ML and Digital Health Technology initiative in psychiatry and neuroscience to join this program. Beyond clinical trials, Deliberate AI is refining AI-COA for use in clinical encounters and psychotherapy settings, aiming to enable more precise triage and replace traditional patient surveys with passive background monitoring for enhanced measurement-based care. The company is also conducting research and development for other mental health conditions, including PTSD, suicide risk, OCD, and schizophrenia.

Key customers and partnerships

Deliberate AI's customers include the Defense Advanced Research Project Agency (DARPA), for a project to improve suicide risk assessment, as well as clinical trial sponsors and mental health clinics. Deliberate AI has also garnered support from global experts in the field of psychiatry. Dr. Maurizio Fava, Associate Dean for Clinical & Translational Research at Harvard Medical School and Psychiatrist-In-Chief at Mass General, has endorsed the company's approach. Similarly, Dr. Rene Kahn, Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai, has expressed support for the potential of AI-COA to revolutionize psychiatric care.